Limmroth V, Reischl J, Mann B, Morosov X, Kokoschka A, Weller I, Schreiner T
Clinic for Neurology and Palliative Medicine, Municipal Hospital Köln-Merheim, Cologne.
Bayer Vital GmbH, Leverkusen.
Patient Prefer Adherence. 2017 Aug 3;11:1325-1334. doi: 10.2147/PPA.S137741. eCollection 2017.
Autoinjectors are well-established in supporting multiple sclerosis (MS) therapy. This market survey was aimed at investigating patients' rating of three devices for subcutaneous interferon beta formulations: the electronic autoinjectors Betaconnect and RebiSmart™ as well as the mechanical ExtaviPro™ device.
Organization and conduction of structured face-to-face interviews in five German cities were managed through an independent external market research company. After questionnaire validation (n=15), 85 participants currently either using the Betaconnect (n=39), the RebiSmart (n=36) or the ExtaviPro injector (n=10) were asked 22 questions in the same order. First, patients named their current device in use, watched the corresponding instruction video, and were queried about their device. Second, patients were asked about their opinion of an ideal autoinjector. Third, instruction videos for the two non-used devices were presented and participants could dummy-inject into a pillow. Last, patients evaluated device features and indicated their preferred autoinjector.
Before having been presented the two other autoinjectors not in use, evaluation of patients' satisfaction with their own device revealed that 82% of the Betaconnect users, 67% of the RebiSmart and 60% of the ExtaviPro users were highly satisfied. All patients desired some improvement of their own device particularly concerning optimization of size and handling. Subsequent to testing and watching instruction videos of all devices, the Betaconnect received the best rating regarding different functions. Finally, participants indicated their preferred autoinjector, provided their own medication was suitable for all three devices: 56.5% of the participants (n=48/85) chose the Betaconnect, 36.5% the RebiSmart (n=31/85), and 5% the ExtaviPro device (n=4/85); 2% did not answer (n=2/85).
In this survey, the Betaconnect device was the preferred autoinjector and may currently best meet patients' needs. As it was closest to participants' opinion of an ideal device, the Betaconnect might contribute to treatment adherence. Our results need to be confirmed in further studies.
自动注射器在支持多发性硬化症（MS）治疗方面已得到广泛应用。本次市场调查旨在研究患者对三种皮下注射干扰素β制剂设备的评价：电子自动注射器Betaconnect和RebiSmart™，以及机械装置ExtaviPro™。
通过一家独立的外部市场研究公司在德国五个城市组织并开展结构化面对面访谈。在问卷验证（n = 15）后，85名目前正在使用Betaconnect（n = 39）、RebiSmart（n = 36）或ExtaviPro注射器（n = 10）的参与者按相同顺序被询问了22个问题。首先，患者说出他们当前正在使用的设备，观看相应的操作指南视频，并被询问有关他们设备的情况。其次，询问患者对理想自动注射器的看法。第三，展示两种未使用设备的操作指南视频，参与者可以对着枕头进行模拟注射。最后，患者评估设备功能并指出他们更喜欢的自动注射器。
在展示另外两种未使用的自动注射器之前，对患者对自己设备的满意度评估显示，82%的Betaconnect用户、67%的RebiSmart用户和60%的ExtaviPro用户高度满意。所有患者都希望对自己的设备进行一些改进，特别是在尺寸和操作的优化方面。在测试并观看了所有设备的操作指南视频后，Betaconnect在不同功能方面获得了最佳评价。最后，参与者指出他们更喜欢的自动注射器，前提是他们自己的药物适用于所有三种设备：56.5%的参与者（n = 48/85）选择了Betaconnect，36.5%选择了RebiSmart（n = 31/85），5%选择了ExtaviPro设备（n = 4/85）；2%未作答（n = 2/85）。
在本次调查中，Betaconnect设备是患者更喜欢的自动注射器，目前可能最能满足患者的需求。由于它最接近参与者对理想设备的看法，Betaconnect可能有助于提高治疗依从性。我们的结果需要在进一步研究中得到证实。
